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Abstract
Rationale: Herein, we present a case of seemingly unprovoked portal vein thrombosis (PVT) occurring in the context of an acute
cytomegalovirus (CMV) infection and prolonged debilitating fatigue.
Patient concerns: A 46-year-old male airline pilot presented with a 2 week history of abdominal pain, nausea, vomiting, watery
diarrhea, and daily recurrent fevers. This was in the context of progressive, debilitating fatigue for 3 months forcing the patient to leave
his job.
Diagnoses:Computed tomography of the abdomen revealed PVT, which wasmanaged initially by heparin infusion. Cefepime was
ordered for broad-spectrum antibiotic management of sepsis and possible septic thrombosis. Further workup exposed elevated
transaminases consistent with mild hepatitis without synthetic dysfunction and colonoscopy revealed colitis. A comprehensive
evaluation for liver disease was notable for a markedly elevated ferritin level. Spiking fevers and neutrophilia persisted for several days
despite empiric antimicrobial treatment, but eventually resolved. The remainder of the workup was negative except for positive CMV
IgM titer and viral load. This raised suspicion for a hypercoagulable state caused by CMV hepatitis with CMV-induced PVT. Heparin
was transitioned to warfarin at the time of discharge.
Interventions: Given the patient’s immunocompetent state and resolution of fevers, antiviral therapy for CMV infection was not
initiated.
Outcomes: The patient continued to improve with a normalization of the serum ferritin level and anticoagulation therapy was
stopped after 6 months.
Lessons: There is mounting support for infectious causes of venous thromboembolism (VTE) based on existing molecular biology
and clinical research. Meta-analysis of existing data showed that between 1.9% and 9.1% of patients hospitalized with VTE had
concurrent acute CMV infection. Theoretical mechanisms for this association include transient formation of antiphospholipid
antibodies, transient formation of antibodies targeting CMV capsule phospholipids with procoagulant properties, and direct infection
of the endothelial cells. We hope this casewill serve as a reminder to consider CMV as a transient cause of PVT and VTE, particularly in
light of 2016 guidelines for unprovoked VTE recommending lifelong anticoagulation. We also plan to prospectively study the
association of unprovoked VTE and acute CMV infection in our own hospital system.
Abbreviations: b2GPI = beta-2-glycoprotein I, APS = antiphospholipid syndrome, CMV = cytomegalovirus, PVT = portal vein
thrombosis, VTE = venous thromboembolism.
Keywords: CMV, coagulopathy, cytomegalovirus, portal vein thrombosis, PVT, venous thromboembolism, VTE
1. Introduction
Unprovoked venous thromboembolism (VTE) is a common
diagnosis, resulting in thousands of patients being placed on
anticoagulation without a clear understanding of the underlying
cause of coagulopathy. In such cases, cytomegalovirus (CMV) is
rarely considered as a possible provoking agent; however, there is
emerging data supporting its role as a cause of a transient
hypercoagulable state. Herein, we present a case of CMV-
induced portal vein thrombosis (PVT) along with a literature
review of similar cases.
2. Case history
A46-year-old male airline pilot presented as a regional transfer to
our facility with progressive abdominal pain for the prior 2
weeks. This was further characterized as a stabbing periumbilical
pain associated with nausea, vomiting, watery diarrhea, and
recurrent daily fevers over the same period of time. Further
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history revealed that the patient had been out of work for 3
months due to progressive, debilitating fatigue. Watery diarrhea
was occurring approximately twice daily without any associated
weight loss. Earlier in the week, the patient had been treated
empirically by his primary care physician with a course of
azithromycin without any improvement. Social history was not
signiﬁcant, as the patient did not smoke cigarettes, use other
tobacco products, or use illicit drugs. In addition, he had avoided
alcohol for most of his life due to his profession as a pilot. The
patient was unmarried and had not been sexually active in several
years. Past medical history was similarly noncontributory, as the
patient denied having any known chronic conditions or
prolonged hospitalizations and denied taking any medications
or supplements. His family history was only signiﬁcant for
Hashimoto disease in his mother, sister, and maternal aunt.
Physical examination was notable for a fever of 38.6 °C,
tachycardia averaging 105 beats per minute, and abdominal
tenderness to deep palpation of the periumbilical area and the
right upper quadrant. The liver span was 13cm at the
midclavicular line by percussion, suggestive of mild hepatomeg-
aly. He did not have any notable rash, lymphadenopathy,
palpable splenomegaly, or any other stigmata of liver disease.
There were also no warm, swollen, tender, or immobile joints
upon musculoskeletal examination.
Initial laboratory ﬁndings were consistent with mild hepatitis
with elevated transaminases, mild hyperbilirubinemia, and mild
hypoalbuminemia without coagulopathy or hyperammonemia
(Table 1). The patient also had mild hyponatremia, elevated C-
reactive protein, and elevated lactate dehydrogenase levels. The
initial blood counts showed mild neutrophilia, atypical lympho-
cytes, and rare smudge cells. Prior to transfer, computed
tomography of the abdomen with contrast revealed PVT
(Fig. 1A, B). This was conﬁrmed by abdominal ultrasound with
portal vein duplex showing retrograde ﬂow and a visible
thrombus with normal echogenicity of the liver. With persistent
fevers and concern for septic thromboembolism, continuous
heparin infusion and intravenous cefepime antibiotic therapy (2g
every 8hours) were initiated on arrival. Further evaluation for
liver disease revealed a ferritin level of 6248ng/mL (Table 2),
which was not accompanied by any other clinical or laboratory
evidence of hemochromatosis. Additional workup for liver
disease revealed moderately low alpha-1-antitrypsin levels,
though the patient did not display other classic signs of the
disease.
As the workup progressed, the patient continued to have daily
fever spikes and neutrophilia, despite empiric antimicrobial
treatment and negative blood and stool cultures (Table 3).
Testing for human immunodeﬁciency virus was negative;
however, the remainder of the evaluations for both fever and
hepatitis revealed a positive CMV IgM titer and abnormal
hepatitis B and C ﬁndings. Viral loads for both hepatitis viruses
were negative, but CMV viral titers were markedly elevated,
supporting the diagnosis of an active CMV infection. On hospital
day 5, fevers ceased and did not recur. The patient was
transitioned from heparin to warfarin for discharge.
The diffuse nature of our patient’s disease processes with
objective ﬁndings of pathology in both the liver and colon, in
addition to the PVT, strongly suggested CMVwas the underlying
etiologic agent. This ﬁt with the history of a viral prodrome along
with the ﬁnding of atypical lymphocytes in the peripheral smear.
However, due to his immunocompetent state and resolution of
fevers, we did not favor antiviral therapy for the CMV infection
at the time of discharge.
3. Differential diagnosis
As part of the initial evaluation, the differential diagnosis for the
fever was considered in the context of watery diarrhea and
thrombosis. Prior to admission, workup for his fevers had
included complete blood counts, a metabolic panel, chest X-ray,
urinalysis, and urine cultures. He also received empiric therapy
with azithromycin. Without a proven infectious source on those
studies, we ﬁrst focused on infectious diarrhea and bacteremia;
however, all cultures resulted negative. Other causes such as
pharyngitis, cholecystitis, and intraabdominal abscess were ruled
out by physical examination and imaging studies. Septic
thrombus was also considered unlikely due to the lack of
positive blood cultures. As these ﬁndings returned negative, and
he approached the 3-week mark of fevers, fever of unknown
origin was more strongly considered. Drug-induced fever was
considered unlikely due to the lack of any medications or
supplements being taken prior to the onset of fevers. Before the
consideration of rarer causes, such as tuberculosis or parasitic
infections, several viral infections were tested.
This paired well with a similar ongoing work-up for hepatitis.
The patient had mild, but new and persistent transaminitis and
hyperbilirubinemia without evidence of synthetic liver dysfunc-
tion. In the context of PVT, our gastroenterology consultant
recommended evaluation for underlying liver disease and they
proceeded with a colonoscopy to evaluate for colitis due to the
persistent diarrhea. Hyperferritinemia was notable, but was an
isolated feature. This ruled out hemochromatosis and many
autoimmune conditions, such as adult Still disease due to the lack
of arthralgias, rash, or pharyngitis. As mentioned above, the
alpha-1-antitrypsin level was also noted to be low, so
Table 1
Initial laboratory studies.
Study Value Normal range
Sodium 134mmol/L 136–145mmol/L
Potassium 4.0mmol/ 3.5–5.1mmol/L
CO2, venous 23mmol/L 22–30mmol/L
Creatinine, blood 0.76mg/dL 0.70–1.30mg/dL
Lactic acid 1.6mmol/L 0.7–2.1mmol/L
Total bilirubin 1.6mg/dL 0.2–1.2mg/dL
Direct bilirubin 0.7mg/dL 0.0–0.5mg/dL
Alkaline phosphatase 150U/L 40–150U/L
Aspartate aminotransferase 90U/L 5–34U/L
Alanine aminotransferase 148U/L 0–55U/L
Gamma glutamyl transferase 117U/L 12–64U/L
Total protein 6.1g/dL 6.3–8.2g/dL
Albumin 3.1g/dL 3.5–5.0g/dL
Ammonia 30mmol/L 18–72mmol/L
International normalized ratio 1.1 0.9–1.2
Partial thromboplastin time 35 sec 24–36 sec
Fibrinogen 236mg/dL 185–475mg/dL
White blood cell 11.79 cells per microliter 4.00–12.00 cells
per microliter
Absolute neutrophil count 8.25 cells per microliter 1.40–5.30 cells
per microliter
Hemoglobin 15.6g/dL 13.0–16.5g/dL
Platelet 144 platelets
per microliter
140–440 platelets
per microliter
CRP 7.05mg/dL <0.50mg/dL
Erythrocyte sedimentation rate 2 mm/h 0–15mm/h
Lactate dehydrogenase 577U/L 125–220U/L
Ethanol <10mg/dL <10mg/dL
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phenotyping was sent, revealing an SZ phenotype. This is
associated with a low alpha-1-antitrypsin level without always
carrying the classic disease presentation of the ZZ phenotype.
For a number of reasons, including a viral pattern of the
transaminases, viral hepatitis was the favored etiology. Both
hepatitis B and C had somewhat abnormal antibody testing,
but proved negative on polymerase chain reaction testing
(Table 2). Ultimately, what conﬁrmed the diagnosis of CMV
was the positive IgM titer and a high viral load by polymerase
chain reaction. This was supported by the ﬁnding of
approximately 10% atypical lymphocytes noted on the
peripheral smear after admission. We suspect that the CMV
infection was responsible for viral hepatitis, which caused PVT,
and colitis, which caused watery diarrhea. When considering
the elevated CMV IgG titer in the setting of detectable CMV
viremia, these ﬁndings are consistent with a chronic active
infection that would account for the chronic fatigue-like
syndrome exhibited by our patient.
Figure 1. The arrows point to hypoattenuated areas that represents parts of the thrombus: (A) this image depicts the portal vein thombus in the extra-hepatic portal
vein; (B) this image depicts the portal vein thombus at branchpoint to the anterior right main portal vein. These images were generated by computed tomography of
the abdomen and pelvis, performed with intravenous contrast dye.
Table 2
Portal vein thrombosis and hepatitis laboratory studies.
Study Value Normal range
Ferritin 6248ng/mL 22–274ng/mL
Iron 28mg/dL 31–144mg/dL
Transferrin 126mg/dL 174–364mg/dL
Iron saturation 18% 15%–62%
PNH ﬂow cytometry Normal phenotyping results
No PNH clone is detected
Normal phenotyping results
No PNH clone is detected
Antihepatitis A IgM Not detected Not detected
Antihepatitis B Core IgM Intermediate Not detected
Hepatitis B surface antigen Not detected Not detected
Hepatitis C antibody 1.09 Signal cutoff ratio <1.0 signal cutoff ratio
Hepatitis B viral load 0 international units per milliliter 0 international units per milliliter
Hepatitis C viral load Not detected Not detected
Carcinoembryonic antigen 0.8ng/mL 0.0–3.0ng/mL
Antismooth muscle antibody <1:10 titer <1:10 titer
Antimitochondrial antibody <1:10 titer <1:10 titer
Ceruloplasmin 32mg/dL 20–60mg/dL
Alpha-1-antitrypsin 61mg/dL 100–190mg/dL
Alpha-1-antitrypsin phenotype SZ phenotype MM phenotype
Human immunodeﬁciency virus antibody and antigen Not detected Not detected
Epstein–Barr virus antigen IgG >3.50 IgG phospholipid units <0.90 IgG phospholipid units
Epstein–Barr virus antigen IgM 0.22 IgM phospholipid units <0.90 IgM phospholipid units
CMV virus IgG >3.50 IgG phospholipid units <0.90 IgG phospholipid units
CMV virus IgM 5.23 IgM phospholipid units <0.90 IgM phospholipid units
CMV quantitative PCR 3220 international units per milliliter 0 international units per milliliter
CMV= cytomegalovirus, PCR=polymerase chain reaction, PNH=paroxysmal nocturnal hematuria.
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4. Outcomes and follow-up
The patient continued to improve after discharge with only
anticoagulation. Ferritin and C-reactive protein trended down
and have since normalized. Anticoagulation was stopped after 6
months of therapy. Additional workup following discharge for
autoimmune disease, hypercoagulability including antiphospho-
lipid syndrome (APS) and genetic mutations, and lyme disease
have been negative thus far (Tables 3 and 4). The resolution of his
fevers, diarrhea, hepatitis, and chronic fatigue is suggestive of full
viral clearance and completed seroconversion from IgM to IgG,
though this could not be conﬁrmed as the patient did not follow-
up with the infectious disease specialist.
5. Discussion
When assessing the etiology of VTE, infectious causes such as CMV
are rarely considered. However, there is mounting evidence to the
contrary.At the timeof preparing this case report, a literature review
of accessible sources revealed 28 cases documented in several case
reports and case series describing immunocompetent patients
presenting with CMV-induced VTE (Tables 5 and 6). Common
features included fever and abdominal pain. However, chronic
fatigue was very uncommon and none of the cases described a
prolonged prodrome of symptoms.[1–22] A recent meta-analysis
showed that between 1.9% and 9.1% of patients hospitalized with
VTE had concurrent acute CMV infection.[23]
Currently, the most plausible mechanism of CMV-induced
VTE involves formation of APS antibodies in response to CMV
infection with resulting transient hypercoagulable state. Several
case studies have described the formation of anticardiolipin
antibodies in acute CMV in humans.[24] In mice models, the
immunological pathways have been studied in greater detail.
Through this process, one CMV-derived peptide of particular
interest, TIFI, was found to be an analog of human beta-2-
glycoprotein I (b2GPI). Mice injected with TIFI developed APS
antibodies and measurable lupus anticoagulant activity, resulting
in more thrombotic events than controls.[25] Translation to
humans was postulated by formation of anti-b2GPI antibodies
against TIFI which would bind endogenous human b2GPI on the
surface of endothelial cells leading to activation of the
coagulation cascade.[26] This model was taken 1 step further
when it was demonstrated that injection of TIFI along with APS
antibodies had a protective effect from VTE in mice.[27] The
development of APS antibodies in patients with acute CMV
infection has not been consistently demonstrated in case studies,
but this appears to be a most promising avenue for further study.
Another possible mechanism involves the immune response to
accessible CMV envelope procoagulant phospholipids, such as
Table 4
Follow-up hypercoagulability studies.
Study Value Normal range
Factor II (prothrombin) Mutation Normal Normal (homozygous wild-type)
Factor V (leiden) mutation Normal Normal (homozygous wild-type)
MTHFR DNA mutation Negative Negative
Protein C activity 141% 79%–175%
Protein S activity 72% 65%–129%
Antithrombin III activity 90% 82%–139%
Anticardiolipin IgG 3.8 IgG phospholipid antigen units per millilitre 0–11.9 IgG phospholipid antigen units per milliliter
Anticardiolipin IgM 6.5 IgM phospholipid antigen units per millilitre 0–11.9 IgM phospholipid antigen units per milliliter
Anticardiolipin IgA 1.8 IgA phospholipid antigen units per millilitre 0–9.9 IgA phospholipid antigen units per milliliter
Beta-2-glycoprotein IgG 11.1 IgG phospholipid antigen units per millilitre <20.0 IgG phospholipid antigen units per milliliter
Beta-2-glycoprotein IgM 8.1 IgM phospholipid antigen units per millilitre <20.0 IgM phospholipid antigen units per milliliter
Beta-2-glycoprotein IgA 2.8 IgA phospholipid antigen units per millilitre <20.0 IgA phospholipid antigen units per milliliter
Lupus anticoagulant Negative Negative
Table 3
Additional laboratory studies.
Study Value Normal range
Peripheral blood smear ∼10% atypical lymphocytes, rare smudge cells present, and
largely normal RBC morphology
Normal
Blood cultures No growth to date after 5 d No growth to date after 5 d
Urinalysis Normal Negative/normal
Stool culture Negative Negative
Clostridium difﬁcile PCR Negative Negative
Colonic biopsy, random Colonic mucosa with prominent intramucosal lymphoid
aggregates. Negative for microscopic colitis. Trichrome
stain demonstrates normal subepithelial collagen thickness.
Normal mucosa
Thyroid stimulating hormone 1.237 milli-international units per liter 0.300–5.000 milli-international units per liter
Lyme antibody 0.44 immune status ratio <0.90 immune status ratio
Antinuclear antibody Negative Negative
Extracted nuclear antigen panel Negative Negative
Anticyclic citrullinated peptide antibody 19 units <20 units
PCR=polymerase chain reaction, RBC= red blood cell.
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phosphatidylserine. This would theoretically allow these com-
pounds to bypass components of the coagulation cascade to
active thrombin through inhibition of innate anticoagulants.[28]
Alternatively, direct infection of endothelial cells by CMV has
long been suggested as the pathophysiology behind this
association of CMV with both venous and arterial thromboem-
bolic events. This invokes Virchow triad, focusing on the role of
endothelial damage in thrombosis. In this model, infection of the
endothelial cells leads to lysis and release of tissue factor-
mediated thrombin, inhibition and depletion of natural anti-
coagulants like antithrombin III, and inhibition of ﬁbrinolysis.[29]
Although one or more of the above mechanisms might be the
cause of this theoretical procoagulant state, the effect appears to
be transient. This was demonstrated in case studies where there
was clearance of anticardiolipin antibodies several months after
CMV infection and acute VTE.[23] One prospective study
speciﬁcally described a window period of approximately
6-month postinfection where there appeared to a higher rate
of VTE than the control population.[30] This is especially
important in the context of the 2016 update to VTE guidelines
published by the American Thoracic Society, which called for
consideration of chronic anticoagulation in all patients with new,
unprovoked VTE.[31] If there is a subset of patients with transient
or reversible causes of hypercoagulability, we need to actively
identify them, as lifelong anticoagulation would be unnecessary
and potentially harmful.
Table 6
Literature review (demographic and pertinent clinical characteristics of reported cases of venous thromboembolism occurring in the
context of acute cytomegalovirus infection in an immunocompetent host).
Article, y
Onset
(age) Gender Presenting complaint VTE location
Hypercoagulable
state/risk factors
Extra-vascular
manifestation Treatment
Pichenot et al (2013)[13] 39 M Monosyndrome, abdominal pain PVT, PE None CMV viremia Warfarin, valgancyclovir
Pichenot et al (2013)[13] 40 F Diarrhea PVT OCP CMV viremia Warfarin
Pichenot et al (2013)[13] 43 F Fever, purpura, arthralgia Bilateral DVT, PE Heavy smoking None Warfarin, gancyclovir
Galloula et al (2014)[14] 24 F NR PVT OCP NR Warfarin
Nakayama et al (2014)[15] 19 M Fever, hemoptysis, right chest pain DVT, PE APL Alveolar hemorrhage,
CMV viremia
Warfarin
Rinaldi et al (2014)[16] 62 F Fever, abdominal pain PVT Smoker CMV hepatitis Warfarin, gancyclovir
Rinaldi et al (2014)[16] 20 F Abdominal pain, headache PVT None CMV hepatitis Enoxaparin
Vandamme et al (2014)[17] 30 M Fever, left chest pain, gastroenteritis Bilateral PE None Myopericarditis, pulmonary
hemorrhage
NR
Bertoni et al (2015)[18] 39 M FUO, monosyndrome Mesenteric vein
thrombosis
Factor V leiden NR Warfarin
Wang et al (2015)[19] 61 M Chronic fatigue, dyspnea,
night sweats, productive cough
PVT None None Warfarin
Chou et al (2016)[20] 78 M Fever, diarrhea PE NR CMV colitis Heparin, gancyclovir
Bountouris et al (2017)[22] 25 M Fever, cough, chest pain DVT, PE None NR rivaroxaban
Vael et al (2017)[21] 58 F Fever, abdominal pain,
chronic fatigue
PVT None CMV colitis Thrombolysis, right
hemicolectomy, heparin
Kelkar et al (2017) 46 M FUO, abdominal pain,
emesis, diarrhea
PVT None CMV viremia, suspected
CMV hepatitis,
suspected CMV colitis
warfarin
APL= antiphospholipid antibodies, CMV= cytomegalovirus, DVT=deep vein thrombosis, F= female, FUO= fever of unknown origin, LLE= left lower extremity, M=male, NR=not reported, OCP= oral
contraceptive pills, PE=pulmonary embolism, PMH=past medical history, PVT=portal vein thrombosis, RLE= right lower extremity, VTE= venous thromboembolism.
Table 5
Literature review (demographic and pertinent clinical characteristics of reported cases of venous thromboembolism occurring in the
context of acute cytomegalovirus infection in an immunocompetent host).
Article, y
Onset
(age) Gender Presenting complaint VTE location
Hypercoagulable
state/risk factors
Extra-vascular
manifestation Treatment
Estival et al (2001)[1] 31 F Fever, lymphadenopathy PVT Heavy smoker, OCP CMV viremia, CMV hepatitis NR
Ofotokun et al (2001)[2] 50 M Fever, abdominal pain PVT None CMV viremia, splenomegaly Gancyclovir
Abgueguen et al (2003)[3] 32 F Fever, dyspnea, left chest pain DVT, PE Factor V leiden (heterozygous) NR NR
Abgueguen et al (2003)[3] 38 F Fever, diarrhea DVT, PE None CMV colitis NR
Youd et al (2003)[4] 35 M Fevers, night sweats, weight loss PE NR CMV hepatitis NR
Rovery et al (2005)[5] 33 M Fever, epigastric pain, RLE pain Tibial popliteal DVT DVT history, factor V leiden
(heterozygous), strong family history
CMV viremia NR
Paran et al (2007)[6] 21 F LLE pain Femoral popliteal DVT Positive anticardiolipin antibodies NR NR
Paran et al (2007)[6] 35 M Fever, chest pain Tibial popliteal DVT Factor V leiden (heterozygous),
MTHFR mutation (Homozygous)
NR NR
Paran et al (2007)[6] 29 F Fever, dyspnea Bilateral DVT OCP NR NR
Squizzato et al (2007)[7] 34 M Fever, cough PVT None Splenomegaly Warfarin
Ergas et al (2008)[8] 28 M Fever, right ﬂank pain Mesenteric vein
thrombosis, PE
MTHFR (heterozygous),
strong family history
NR NR
Ladd et al (2009)[9] 17 F Fever, RUQ abdominal pain PVT, PE OCP NR NR
Poon et al (2011)[10] 30 F Fever, myalgia, cough PE NR Splenic infarct Warfarin
Kalaitzis et al (2012)[11] 40 M Fever, weight loss Mesenteric vein thrombosis None CMV viremia,
small bowel necrosis
Enoxaparin
Sherman et al (2012)[12] 70 M FUO, headache Sinus vein thrombosis None NR Warfarin
APL= antiphospholipid antibodies, CMV= cytomegalovirus, DVT=deep vein thrombosis, F= female, FUO= fever of unknown origin, LLE= left lower extremity, M=male, NR=not reported, OCP= oral
contraceptive pills, PE=pulmonary embolism, PMH=past medical history, PVT=portal vein thrombosis, RLE= right lower extremity, VTE= venous thromboembolism.
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Keeping all of the above in mind, the combination of CMV
viremia and CMV hepatitis likely contributed to the procoagu-
lant state, leading to PVT.[29,32] These features likely also
contributed to the prolonged debilitating fatigue prodrome,
which was a unique feature in this case, as it suggested a
prolonged failure to clear the virus, despite the patient’s
immunocompetent status. Although our patient did not require
antiviral therapy, further study into the possible beneﬁts of such
therapy in cases with immunocompetent patients is war-
ranted.[33] We hope this case will support further study of the
mechanisms linking CMV to VTE and provide additional
testimony for consideration of acute CMV infection as a
procoagulant state by clinicians in practice. We are also planning
further study of our own in the form of retrospective analysis of
hypercoagulability in CMV patients and prospective testing for
CMV seropositivity in new cases of unprovoked VTE.
6. Methods
Informed consent from the patient was requested and obtained
from the patient. Ethical approval from our Institutional Review
Board was not necessary as this is a case report maintains the
anonymity of the patient.
7. Patient perspective
The patient was offered the option to share his written
perspective, but he politely refused the request. The authors
would like to thank our patient for allowing for his case to be
presented.
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